The BRIJ network

Australia’s national science agency has developed 5,000+ patents and 150+ spin-offs. At BRIJ’s Ecosciences Precinct, CSIRO teams advance areas including environmental science, engineering biology, and sustainable resource management.

DETSI is fostering a thriving environment and economy for Queensland’s current and future generations. The department delivers evidence-based science and policies for environment, biodiversity and resource management while advancing sustainable tourism, innovation and research translation for economic and ecological benefit.

DPI ensures Queensland’s primary industries are productive profitable, productive and sustainable.

They work with industry, communities and the government to grow the economy, strengthen rural communities, safeguard against biosecurity threats, and ensure long-term food, fibre, timber and renewable fuel security for Queensland and beyond.

Coordinating Queensland’s infrastructure strategy and economic development. This includes securing major projects, facilitating private sector investment, and streamlining planning frameworks to support industry growth and job creation.

ENTRI is owned and operated by the Translational Research Institute (TRI), opening in early 2026, it will offer on-demand cGMP cleanroom facilities, expert support, and regulatory guidance to help companies scale manufacturing from clinical trials to commercialisation.

Griffith University provides world-leading expertise in drug discovery, clinical trials and pharmaceutical sciences. Ranked in the top 2% of universities worldwide, Griffith advances therapeutic breakthroughs through partnerships with industry, clinicians and research communities and is part of the Translational Science Hub.

Founded in 1998 within the charitable network of the Sisters of Mercy, Mater Research has spearheaded solutions in maternal health, cancer treatment, neuroscience and chronic disease management. Based at the Translational Research Institute, its teams collaborate with Mater Health and The University of Queensland to transform discoveries into improved patient care.

MSH oversees Brisbane’s southern suburbs, including the Princess Alexandra Hospital, a digital public healthcare hub driving medical innovation through collaboration with academia and industry.

Operating next door to TRI, Patheon runs Australia’s sole commercial-grade biologics facility, providing contract drug manufacturing services including cutting-edge mammalian cell cultivation, purification and contamination control.

A fully digital tertiary hospital, PAH enables world-first clinical trials through advanced infrastructure including its TRI Clinical Research Facility. It hosts the Australian Centre for Complex Integrated Surgical Solutions and early-adopted technologies such as the Gamma Knife® and Vectra body scanner.

The QCS is a whole-of-government position sitting within DETSI. It provides independent high-level strategic advice to the state government on the role of science, research and innovation to meet Queensland’s challenges. The QCS champions the importance of science for our society, economy and environment, and promotes Queensland’s leadership in scientific research, partnerships and translation.

Queensland Health delivers accessible, high-quality care to more than five million people through 16 hospital and health services across the state, including Princess Alexandra Hospital at BRIJ. In partnership with TRI, Queensland Health transforms research into clinical solutions that improve health outcomes across Australia.

QIC is a government owned, Australian investment manager and acts as the State’s independent investment adviser, while delivering alternative real asset solutions across real estate, private equity and other sectors for ~110 global clients with A$127.3bn AUM (as at 31 March 2025). QIC plays an important role in the active leadership of BRIJ as well as being the master developer of key expansion opportunities.

Ranked among Australia’s top universities for commercialisation success, QUT specialises in translating research into market-ready health innovations. Through its integration with TRI, QUT combines next-generation talent development with translational research, building on Australia’s highest rated biomedical engineering research and over 100 active industry collaborations.

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi is part of Translational Science Hub at BRIJ.

Ranked in the global top 50 and one of Australia’s leading universities, UQ collaborates with 400+ industry and government partners across drug discovery, therapeutics and vaccine development, biotechnology and sustainability, agriculture and food innovation, AI and quantum technologies.

UQ is a key partner at TRI and part of the Translational Science Hub, working closely with PAH and other Australian hospitals to develop products from concept to clinical trials. The School of Pharmacy has operated from its state-of-the-art A$10m facility opposite PAH since 2010, fostering industry and government partnerships that advance pharmaceutical sciences while creating a talent pipeline feeding directly into BRIJ’s specialised workforce.

TRI is a global leader in the effective translation of research and innovation into improved healthcare. A unique partnership between The University of Queensland, Queensland University of Technology, Mater Research and Queensland Health, TRI’s collaborative ecosystem has delivered powerful impact since opening in 2012.